{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:01:09Z","timestamp":1790020869675,"version":"4.0.1"},"reference-count":0,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:p>Regulator of G protein signaling-2 (RGS-2) plays a key role in the G protein-coupled receptor (GPCR) angiotensin II (Ang II) signaling. NO and cGMP exert a vasodilating action also through activation and binding to RGS-2 of cGMP dependent protein kinase 1-\u03b1, which phosphorylates RGS-2 and dephosphorylates myosin light chain. In Bartter\u2019s\/Gitelman\u2019s patients (BS\/GS) Ang II related signaling and vasomotor tone are blunted. Experiments were planned to explore whether RGS-2 may play a role in BS\/GS vascular hyporeactivity. NO metabolites and cGMP urinary excretion were also measured. Mononuclear cells (PBM) from six BS\/GS patients and six healthy controls were used. PBM RGS-2 mRNA and RGS-2 protein were increased in BS\/GS: 0.47 \u00b1 0.06 d.u. vs 0.32 \u00b1 0.04, (p &amp;lt; 0.006) (RGS-2 mRNA), and 0.692 \u00b1 0.02 vs 0.363 \u00b1 0.06 (p &amp;lt; 0.0001) (RGS2 protein). Incubation of PBM with Ang II increased RGS-2 protein in controls (from 0.363 \u00b1 0.06 d.u. to 0.602 \u00b1 0.05; p &amp;lt; 0.0001) but not in BS\/GS (from 0.692 \u00b1 0.02 to 0.711 \u00b1 0.02). NO2-\/NO3- and cGMP urinary excretion were increased in BS\/GS (0.46 \u00b1 0.13 vs 0.26 \u00b1 0.05 \u03bcmol\/\u03bcmol of urinary creatinine, p &amp;lt; 0.005, and 0.060 \u00b1 0.030 vs 0.020 \u00b1 0.01 p &amp;lt; 0.009, respectively). These results demonstrate that RGS-2 is increased and maximally stimulated in BS\/GS and human RGS-2 system reacts as predicted by knockout mice experiments. This is the first report of RGS-2 level in a human clinical condition characterized by altered vascular tone, underlines the importance of RGS-2 as a key regulator element for Ang II signaling and provides insight into the links between BS\/GS genetic abnormalities and abnormal vascular tone regulation.<\/jats:p>","DOI":"10.1210\/jc.2004-0498","type":"journal-article","created":{"date-parts":[[2004,8,3]],"date-time":"2004-08-03T21:40:43Z","timestamp":1091569243000},"page":"4153-4157","source":"Crossref","is-referenced-by-count":78,"title":["Increased Expression of Regulator of G Protein Signaling-2 (RGS-2) in Bartter\u2019s\/Gitelman\u2019s Syndrome. A Role in the Control of Vascular Tone and Implication for Hypertension"],"prefix":"10.1210","volume":"89","author":[{"given":"Lorenzo A.","family":"Calo\u0300","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Clinica Medica 4 (L.A.C., E.P., M.S., G.C., A.C.P., A.S.), University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pagnin","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Clinica Medica 4 (L.A.C., E.P., M.S., G.C., A.C.P., A.S.), University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (P.A.D.), University of California-Davis, Davis, California 95616"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Sartori","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Clinica Medica 4 (L.A.C., E.P., M.S., G.C., A.C.P., A.S.), University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Ceolotto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Clinica Medica 4 (L.A.C., E.P., M.S., G.C., A.C.P., A.S.), University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille C.","family":"Pessina","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Clinica Medica 4 (L.A.C., E.P., M.S., G.C., A.C.P., A.S.), University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Semplicini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Clinica Medica 4 (L.A.C., E.P., M.S., G.C., A.C.P., A.S.), University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/8\/4153\/9147302\/jcem4153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/8\/4153\/9147302\/jcem4153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:24:45Z","timestamp":1594956285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/89\/8\/4153\/2844781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2004-0498","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,1]]}}}